Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sylentis, S.A.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients older than 18 years of either sex
Good or fair general health as assessed by the investigator.
Signed informed consent prior to any clinical trial-related procedures
Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT)
Post-washout mean IOP above target range
BCVA 1.0 logMAR or better by ETDRS in each eye (equivalent to 20/200)
Stable visual field
Central corneal thickness 480-620 μm
Shaffer gonioscopic grade of ≥ 3 (in at least 3 quadrants) in both eyes
You may not be if
Pregnant or breastfeeding females
Females of childbearing potential not willing to use a medically acceptable contraceptive method
Clinically significant systemic disease
Changes of systemic medication that could have a substantial effect on IOP
Known hypersensitivity to any component of the formulations
Unable to comply with the clinical trial requirements
Clinically significant abnormalities in laboratory tests
Severe visual field defect
Any secondary glaucoma
Pseudoexfoliation or pigment dispersion component, history of angle closure or narrow angles.
IOP ≥ 35 mm Hg in any eye
Previous non-laser glaucoma surgery or glaucoma laser procedures (e.g., laser trabeculoplasty) and refractive surgery
Any ocular surgery or laser treatment, cataract extraction or ocular trauma within 6 months prior to Baseline
Evidence of ocular infection, inflammation, clinically significant blepharitis or conjunctivitis at baseline (Visit 0), or a history of herpes simplex keratitis